Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase II Study of UCN-01 in Metastatic Melanoma
NCT00072189 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2015-03-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Early termination for discouraging results” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-11-11Also stopped (terminated): National Cancer Institute (NCI), Alvocidib Hydrochloride + Cyclophosphamide (NCT01076556)
- 2015-09-09Results posted on the registry: National Cancer Institute (NCI), topotecan hydrochloride + 7-hydroxystaurosporine (NCT00098956)
- 2015-08-07Also stopped (terminated): Merck Sharp & Dohme LLC, SCH 727965 + Bortezomib (NCT00871546)
- 2015-07-07Results posted on the registry: National Cancer Institute (NCI), alvocidib + mitoxantrone hydrochloride (NCT00634244)
- 2015-02-04Also stopped (terminated): Merck Sharp & Dohme LLC, SCH 727965 + Gemtuzumab ozogamicin (NCT00798213)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision